IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Japan

  • ID: 1408488
  • Report
  • Region: Japan
  • 73 Pages
  • IMS Health
1 of 3

The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS pricing and reimbursement specialists to provide industry players and decision makers with a thorough understanding of the rules and regulations governing P&R in international markets.

This report covers key developments in P&R, market access, cost containment, trade margins and healthcare issues.

Note: Product cover images may vary from those shown
2 of 3

1. Healthcare System

  • Facts & Figures
  • Market Indicators
  • Provision & Funding
  • Employee Health Insurance
  • National Health Insurance
  • Long Life Medical Care System
  • Background

2. Pricing

  • Prescription Drugs
  • Overview
  • Application
  • Assessment
  • Comparative Price Method
  • Cost Calculation Method
  • International Price Referencing
  • Drugs Designed to Forestall Generic Competition
  • Fixed-dose Combination Drugs
  • Appeals
  • Generic Drugs
  • Pricing Rules
  • Discounts
  • Biosimilars
  • Hospital Drugs
  • OTC Drugs

3. Reimbursement

  • Admission to Reimbursement
  • Application
  • Criteria
  • Assessment
  • Timelines
  • Listing
  • Access to Innovative Medicines
  • Orphan Drugs
  • Reimbursement Categories
  • Reimbursement Prices
  • Hospital Reimbursement
  • Formularies
  • Funding
  • Medical Fees
  • Changes in Reimbursement Status
  • Changes in Reimbursement Prices
  • Biennial Price Revision Process
  • Price Reduction Mechanisms
  • Special Price Premiums
  • Other Mechanisms
  • Impact of Cost-effectiveness Evaluations

4. Pharmacoeconomics

  • Pharmacoeconomic Requirements
  • Information Requirements
  • Guidelines
  • Trial Cost-effectiveness Assessments

5. Price Build Up

  • Wholesalers
  • Margins
  • Background
  • Retail Pharmacies
  • Margins
  • Dispensing Fees
  • Background
  • Dispensing Doctors
  • Sales Tax

6. Cost Containment

  • Industry Paybacks
  • Promotional Costs
  • Patient Co-payments
  • Patients Aged 0-74 Years
  • Patients Aged 75 and Over
  • Unapproved Treatments
  • Non-reimbursed Drugs
  • Prescribing Controls
  • Optimal Usage Guidelines
  • Prescribing Fees
  • Generic Prescribing
  • Generic Substitution
  • Prescribing Limits
  • Other Controls
  • Generics
  • Generic Uptake
  • Generic Substitution
  • INN Prescribing
  • Incentives
  • Price Cuts for Long-listed Drugs
  • Biosimilars
  • Rx-to-OTC Switches
  • Application
  • Assessment
  • OTC Drug Categories
  • Switches
  • Parallel Trade 

7. Future Developments

  • Outlook
  • Annual Price Reviews
  • Quarterly Price Reviews
  • International Price Referencing
  • Changes to Price Premium for New Drugs
  • Other Measures
  • Early Approval System
  • Discussion Timelines

8. Names & Addresses

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll